Evidence map›Paper›PMID 33738673›Full record

ArticleApoptosis : an international journal on programmed cell death2021

The molecular mechanism of a novel derivative of BTO-956 induced apoptosis in human myelomonocytic lymphoma cells.

Yu-Lin Li, De-Jun Zhou, Zheng-Guo Cui, Lu Sun, Qian-Wen Feng, Shahbaz Ahmad Zakki, Yusuke Hiraku, Cheng-Ai Wu, Hidekuni Inadera

Abstract read
PubMed Publisher
In one paragraph

Article in Apoptosis : an international journal on programmed cell death, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Programmed cell death lives.Apoptosis : an international journal on programmed cell death · 2022
    Article
  3. Network Pharmacologic Analysis ofFrontiers in pharmacology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 3 countries.

Yu-Lin Li *Department of Public Health, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, 2630 Sugitani, Toyama, 930-0194, Japan.
De-Jun Zhou *Graduate School of Medicine, Henan Polytechnic University, Jiaozuo, 454000, China.
Zheng-Guo CuiDepartment of Environmental Health, University of Fukui School of Medical Sciences, 23-3 Matsuoka Shimoaizuki Eiheiji, Fukui, 910-1193, Japan.
Lu SunDepartment of Pediatric Cardiology, Heart Center, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, 510623, China.
Qian-Wen FengDepartment of Public Health, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, 2630 Sugitani, Toyama, 930-0194, Japan.
Shahbaz Ahmad ZakkiDepartment of Public Health and Nutrition, The University of Haripur, Hattar Road, Haripur, KP, Pakistan.
Yusuke HirakuDepartment of Environmental Health, University of Fukui School of Medical Sciences, 23-3 Matsuoka Shimoaizuki Eiheiji, Fukui, 910-1193, Japan.
Cheng-Ai WuDepartment of Molecular Orthopaedics, Beijing Research Institute of Traumatology and Orthopaedics, Beijing Jishuitan Hospital, Xicheng District Xinjiekou East Street on the 31st, Beijing, 100035, China. wuchengai@jst-hosp.com.cn.
Hidekuni InaderaDepartment of Public Health, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, 2630 Sugitani, Toyama, 930-0194, Japan. inadera@med.u-toyama.ac.jp.
University of Toyama · JPUniversity of Fukui · JPBeijing Jishuitan Hospital · CNGuangzhou Medical University · CNHenan Polytechnic University · CNUniversity of Haripur · PK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute myeloid leukemia (AML) is a malignant cancer of the hematopoietic system. Although the effectiveness of arsenic compounds has been recognized and applied clinically, some patients are still found resistant to this chemotherapy. In this study, we investigated that a synthetic thyroid hormone analog (TA), 2-iodo-4-nitro-1-(o-tolyloxy) benzene, had a strong apoptosis effect on U937 cells. U937 cells were treated with TA, and examinted the generation of reactive oxygen species (ROS), dysfunction of mitochondria, expression of pro-apoptosis and anti-apoptosis, and cleavage of caspase-3 and Poly (ADP-ribose) polymerase (PARP). Further, it is also evaluated that insight molecular mechanism and signaling pathways involved in the study. It is found that TA significantly induced apoptosis in U937 cells through production of ROS, dysfunction of mitochondria, and activation of caspase cascade. It was also observed that MAPK signaling pathway including ERK, JNK, and P38 signals are involved in the induction of apoptosis. Moreover, marked activation of autophagy and ER stress markers such as LC3, P62, Beclin1 and GRP78, CHOP were observed, respectively. Pretreatment with ER stress inhibitor tauroursodeoxycholic acid (TUDCA) and autophagy inhibitor 3-Methyladenine (3-MA) have successfully attenuated and aggravated TA-induced apoptosis, respectively. We further confirmed the active involvement of ER stress and autophagy signals. In conclusion, TA induced apoptosis through ER stress and activation of autophagy, and the latter is not conducive to TA-induced cell death. Our results may provide a new insight into the strategic development of novel therapy for the treatment of AML.

Indexed as

ApoptosisAutophagyCell Line, TumorEndoplasmic Reticulum Chaperone BiPEndoplasmic Reticulum StressHumansIodobenzoatesLeukemia, MyeloidMAP Kinase Signaling SystemReactive Oxygen SpeciesU937 CellsEndoplasmic Reticulum Chaperone BiPHSPA5 protein, humanIodobenzoatesmethyl 3,5-diiodo-4-(4'-methoxyphenoxy)benzoateReactive Oxygen SpeciesApoptosisAutophagyBTO-956ER stressMAPK PathwayU937 Cells

Identifiers

PMID33738673
OpenAlexW3138514120

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.